AbCellera Results Presentation Deck

2020 BUSINESS UPDATE. COVID-19 PROGRAM ADVANCING A NEW, NEXT-GEN COVID-19 ANTIBODY. In late January, Eli Lilly moved a next-gen antibody discovered by AbCellera, 1404, into preclinical development. This antibody is: ● ● Predicted to neutralize all circulating variant strains of COVID-19, including the South African, UK, New York, Brazilian and California variants Expected to reach clinical testing in 2021 Q2 A potential best-in-class therapeutic ½ + H- Ab Cellera Antibody therapies are a complementary approach to vaccines, both now and in the future.

View entire presentation